GET DAILY SIGNALSEntera Bio Ltd. (ENTX): Analysts See +257% Upside to a $10 Target
Key Takeaways
- The $10 central price target is the rounded arithmetic mean (about $9.60) of five verified analyst price targets, which range from $9.00 to $11.00.
- With Entera Bio Ltd. (ENTX) recently trading near $2.80, reaching $10 would require a roughly 257% gain, a very large move even for a volatile clinical-stage biotech.
- Coverage skews bullish, with recent initiations from Guggenheim, LifeSci Capital, Leerink Partners, Cantor Fitzgerald, and UBS, alongside a maintained Buy from H.C. Wainwright.
- The bull case rests on an FDA-supported Phase 3 design for oral osteoporosis candidate EB613 and optionality in oral GLP-1 obesity treatment.
- The main risks are pre-revenue status, recurring losses, cash burn, dilution, and the binary nature of clinical outcomes.
- For additional context, explore Major News, Today's Price Move, the Forecast, and Earnings pages for this ticker.
- Readers can also explore Trending AI Robots to see how automated strategies are positioning across the market.
Analyst Price Targets and Consensus View
Entera Bio Ltd. (ENTX) is a clinical-stage biopharmaceutical company developing orally delivered peptide therapies using its N-Tab platform. It is a stock, not an ETF, and it currently generates no meaningful product revenue, so its valuation rests almost entirely on clinical execution and pipeline optionality. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The $10 central target reflects an arithmetic mean of five recent, attributable analyst targets. Guggenheim initiated coverage with a Buy and an $11.00 target in late September 2026, LifeSci Capital initiated with Outperform and a $10.00 target, Leerink Partners set a $9.00 Outperform target, UBS set a $9.00 target, and H.C. Wainwright reiterated a Buy with a $9.00 target in June 2026. Cantor Fitzgerald also initiated coverage with an Overweight rating, though no standalone target was reported. The resulting range is $9.00 to $11.00, with a calculated mean near $9.60, rounded to $10 for this analysis.
Bullish, neutral, and cautious views differ sharply. Bulls emphasize a de-risked oral PTH (parathyroid hormone) platform and an FDA-supported Phase 3 trial design, while the lone cautious voice (a sell rating) highlights the execution and financing risks typical of pre-revenue biotech. No analyst target is a guarantee, and the wide gap between the current price and these targets reflects high uncertainty.
Current Market Position and Path Toward the Target
ENTX has traded in an unusually wide 52-week range of $0.91 to $4.20, and recent quotes have hovered near $2.80 after a period of sharp revaluation. At that level, a move to $10 represents roughly 257% upside, which is a very large move by any standard.
The path toward such a level would almost certainly depend on clinical and regulatory milestones rather than near-term fundamentals. Entera Bio's trailing-twelve-month EPS (earnings per share) is about negative $0.36, with a net loss of roughly $17 million and no product revenue, so valuation would need to be re-rated on catalysts such as Phase 3 progress for EB613 in postmenopausal osteoporosis, updates on EB612 for hypoparathyroidism, or further advancement of its oral GLP-1 obesity program developed with OPKO. A substantial equity raise appears to have already expanded the share count, meaning future appreciation must be shared across a larger base.
What Could Support a Move Toward the Target
- An FDA-supported Phase 3 registrational design for EB613, which analysts have framed as a meaningful de-risking event.
- Optionality in oral GLP-1 obesity treatment, one of the highest-conviction areas in biopharma.
- Fresh, positive analyst initiations that signal growing institutional visibility for a company with a roughly $490 million market capitalization.
- A broad pipeline spanning osteoporosis, hypoparathyroidism, and metabolic disorders, which could support multiple value-driving catalysts.
What Could Prevent the Target From Being Reached
- Pre-revenue status and recurring operating losses, with negative EBITDA (earnings before interest, taxes, depreciation, and amortization) of about $14 million.
- Limited cash of roughly $11 million as of mid-2026, which could necessitate further dilutive financing.
- Binary clinical risk: any setback in the Phase 3 osteoporosis program or the oral GLP-1 program could compress the stock quickly.
- The presence of a sell rating and the very wide gap between price and targets, which signals substantial execution uncertainty.
Technical Levels and Market Structure
ENTX has shown extreme volatility, with a 52-week low of $0.91 and a 52-week high of $4.20. The $4.20 level represents the most recent meaningful overhead resistance, while the low-$2 range has acted as a recurring support zone during pullbacks. A sustained move toward $10 would require first reclaiming and holding above $4.20, a level the stock has not yet broken on a durable basis. These are structural reference points rather than near-term trading signals.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms may differ, and no explicit horizon is uniform across the five targets reviewed. Key items to watch include Phase 3 enrollment and data timelines for EB613, any oral GLP-1 program updates, the next earnings report and cash position disclosure, further financing decisions, and analyst target revisions. Given the binary nature of clinical catalysts, timing estimates should be treated cautiously.
Using AI Daily Buy/Sell Signals in My Process
In my research on names like ENTX, I often review AI Daily Buy/Sell Signals from Tickeron. These tools apply artificial intelligence to monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a high-volatility name like this, they help me discover opportunities, monitor positions, and spot shifting trends more efficiently than manual review alone.
Final Assessment
The $10 target for Entera Bio represents a rounded average of five analyst targets spanning $9.00 to $11.00, requiring a roughly 257% rise from a recent price near $2.80. The strongest supports are an FDA-supported Phase 3 osteoporosis design and oral GLP-1 optionality, while the principal obstacles are a pre-revenue model, cash burn, dilution, and binary clinical risk. The unusually wide gap between price and target reflects genuine disagreement about execution rather than consensus conviction. Investors should focus on clinical milestones, financing, and analyst revisions rather than treating $10 as a forecast.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ENTX in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 06, 2026
ENTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 40 of 46 cases where ENTX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ENTX's RSI Indicator exited the oversold zone, 28 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on ENTX as a result. In 81 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for ENTX just turned positive on October 16, 2026. Looking at past instances where ENTX's MACD turned positive, the stock continued to rise in 42 of 53 cases over the following month. The odds of a continued upward trend are 79%.
Following a +3.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENTX advanced for three days, in 180 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 43 cases where ENTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
ENTX moved below its 50-day moving average on October 26, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ENTX crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ENTX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ENTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ENTX's P/B Ratio (72.917) is slightly higher than the industry average of (3.037). P/E Ratio (-8.743) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (1428.571) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of flu medicines
Industry Biotechnology
Advertisement